EP1104486A4 - A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer - Google Patents

A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer

Info

Publication number
EP1104486A4
EP1104486A4 EP99935685A EP99935685A EP1104486A4 EP 1104486 A4 EP1104486 A4 EP 1104486A4 EP 99935685 A EP99935685 A EP 99935685A EP 99935685 A EP99935685 A EP 99935685A EP 1104486 A4 EP1104486 A4 EP 1104486A4
Authority
EP
European Patent Office
Prior art keywords
staging
diagnosing
imaging
monitoring
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99935685A
Other languages
German (de)
French (fr)
Other versions
EP1104486A1 (en
Inventor
Fei Yang
Yongming Sun
Herve Recipon
Roberto A Macina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Publication of EP1104486A1 publication Critical patent/EP1104486A1/en
Publication of EP1104486A4 publication Critical patent/EP1104486A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP99935685A 1998-08-04 1999-07-19 A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer Withdrawn EP1104486A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9523398P 1998-08-04 1998-08-04
US95233P 1998-08-04
PCT/US1999/016247 WO2000008206A1 (en) 1998-08-04 1999-07-19 A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer

Publications (2)

Publication Number Publication Date
EP1104486A1 EP1104486A1 (en) 2001-06-06
EP1104486A4 true EP1104486A4 (en) 2002-07-17

Family

ID=22250833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99935685A Withdrawn EP1104486A4 (en) 1998-08-04 1999-07-19 A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer

Country Status (4)

Country Link
EP (1) EP1104486A4 (en)
JP (1) JP3524061B2 (en)
CA (1) CA2347656A1 (en)
WO (1) WO2000008206A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869592B1 (en) 1998-08-04 2005-03-22 Diadexus, Inc. Method and antibody for imaging lung cancer
US20030017468A1 (en) * 2000-08-28 2003-01-23 Sei-Yu Chen Compositions and methods relating to lung specific genes
JP2004520821A (en) * 2000-10-26 2004-07-15 ディアデクサス インコーポレーテッド Compositions and methods for lung-specific genes and proteins
US20020183500A1 (en) * 2000-11-20 2002-12-05 Roberto Macina Compositions and methods relating to lung specific genes and proteins
WO2002040673A2 (en) * 2000-11-20 2002-05-23 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
WO2002068633A2 (en) * 2000-11-22 2002-09-06 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0695760A1 (en) * 1994-08-05 1996-02-07 F. Hoffmann-La Roche Ag Novel tumor marker for lung cancer
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
WO1998020143A1 (en) * 1996-11-05 1998-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the lung
WO1998056951A1 (en) * 1997-06-11 1998-12-17 Abbott Laboratories Reagents and methods useful for detecting diseases of the lung
WO1999060160A1 (en) * 1998-05-21 1999-11-25 Diadexus Llc A novel method of diagnosing, monitoring, and staging lung cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
EP0695760A1 (en) * 1994-08-05 1996-02-07 F. Hoffmann-La Roche Ag Novel tumor marker for lung cancer
WO1998020143A1 (en) * 1996-11-05 1998-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the lung
WO1998056951A1 (en) * 1997-06-11 1998-12-17 Abbott Laboratories Reagents and methods useful for detecting diseases of the lung
WO1999060160A1 (en) * 1998-05-21 1999-11-25 Diadexus Llc A novel method of diagnosing, monitoring, and staging lung cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0008206A1 *

Also Published As

Publication number Publication date
WO2000008206A1 (en) 2000-02-17
CA2347656A1 (en) 2000-02-17
JP2002522046A (en) 2002-07-23
EP1104486A1 (en) 2001-06-06
JP3524061B2 (en) 2004-04-26

Similar Documents

Publication Publication Date Title
EP1105528A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1082459A4 (en) A novel method of diagnosing, monitoring, and staging lung cancer
EP1239874A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
MXPA01008794A (en) Method of diagnosing and monitoring malignant breast carcinomas.
GB2286844B (en) Wellbore monitoring apparatus
GB2340152B (en) Multiple string completion apparatus and method
EP1123102A4 (en) Method of preventing acute lung injury
ZA9811179B (en) Inhalation apparatus and method.
GB9925449D0 (en) Well logging apparatus and method
GB2303706B (en) Lung function monitoring apparatus flowheads
GB9913323D0 (en) Method and apparatus for the detection of X-rays
GB9826017D0 (en) Well logging method and apparatus
EP1131095A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
IL128531A0 (en) Method for treating heart failure
EP1104486A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer
EP1267934A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1107798A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating colon cancer
IL129629A0 (en) Failure analyzing method and apparatus
GB9826556D0 (en) Apparatus and method for downhole telemetry
AU2001268633A1 (en) Method of diagnosing, monitoring, staging, imaging and treating breast cancer
GB9820919D0 (en) Diagnostic method
EP1082460A4 (en) A novel method of diagnosing, monitoring, and staging prostate cancer
AU2001241656A1 (en) Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
EP1117833A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers
AU2001271621A1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010305

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020604

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7G 01N 33/574 A, 7C 07K 16/30 B, 7C 12Q 1/68 B, 7A 61K 39/395 B

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

17Q First examination report despatched

Effective date: 20030630

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050924